Last reviewed · How we verify

Sasanlimab Prefilled syringe — Competitive Intelligence Brief

Sasanlimab Prefilled syringe (sasanlimab-prefilled-syringe) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: prefilled syringe. Area: Oncology.

discontinued prefilled syringe Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Sasanlimab Prefilled syringe (sasanlimab-prefilled-syringe) — Pfizer Inc.. prefilled syringe

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sasanlimab Prefilled syringe TARGET sasanlimab-prefilled-syringe Pfizer Inc. discontinued prefilled syringe

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (prefilled syringe class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sasanlimab Prefilled syringe — Competitive Intelligence Brief. https://druglandscape.com/ci/sasanlimab-prefilled-syringe. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: